← SynDRA
MIK665
SynDRA canonical compound SYN1969880 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
| Primary target(s) | MCL1 |
| Mechanism of action | mcl1 inhibitor |
| Indication | multiple myeloma |
| Disease area | hematologic malignancy |
All known targets
Mechanisms of action (all sources)
Cross-references
Synonyms
- (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid
- (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid
- MIK-665
- S-64315
- SCHEMBL16815710
- EX-A2912
- NSC809971
- NSC-809971
- HY-112218
- CS-0044179
- (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid
- OK5
- (R)-MIK665
- C47H44ClFN6O6S
- orb1708748
- orb1708749
- SCHEMBL29380367
- SCHEMBL29423551
- SCHEMBL29423555
- GLXC-20221
- GLXC-23152
- BDBM50548802
- MFCD32669779
- AKOS040736224
- AT23541
- HY-112218A
- MIK665; S-64315
- NCGC00689266-02
- DA-55486
- DA-69211
- MS-31625
- CS-0100373
- T12629
Look up MIK665 in the interactive SynDRA portal →